FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2

dc.contributor.author	Renz, Alina
dc.contributor.author	Widerspick, Lina
dc.contributor.author	Dräger, Andreas
dc.date.accessioned	2020-05-07T13:09:08Z
dc.date.available	2020-05-07T13:09:08Z
dc.date.issued	2020
dc.identifier.uri	http://hdl.handle.net/10900/100341
dc.language.iso	en	de_DE
dc.publisher	Oxford : Oxford University Press	de_DE
dc.relation.uri	https://doi.org/10.1093/bioinformatics/btaa813	de_DE
dc.subject.classification	SARS-CoV-2 , COVID-19 , Wirkstoff , Systembiologie , Krankheit , Modellierung , Modell	de_DE
dc.subject.ddc	004	de_DE
dc.subject.ddc	500	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2	de_DE
dc.type	Article	de_DE
utue.kommentar.intern	Zunächst als Preprint auf Zenodo erschienen: https://doi.org/10.5281/zenodo.3752641	de_DE
utue.publikation.seiten	i813–i821	de_DE
utue.personen.roh	Renz, Alina
utue.personen.roh	Widerspick, Lina
utue.personen.roh	Dräger, Andreas
dcterms.isPartOf.ZSTitelID	Bioinformatics	de_DE
dcterms.isPartOf.ZS-Issue	Supplement_2	de_DE
dcterms.isPartOf.ZS-Volume	36	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE